We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

1.
Figure 3

Figure 3. From: Tandem Autologous versus Single Autologous Transplantation Followed by Allogeneic Hematopoietic Cell Transplantation for Patients with Multiple Myeloma: Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial.

Figure 3A: Progression-free survival of high risk auto-auto and auto-allo groups
Figure 3B: Overall survival of high risk auto-auto and auto-allo groups.

Amrita Krishnan, et al. Lancet Oncol. 2011 December;12(13):1195-1203.
2.

Figure 2. From: Tandem Autologous versus Single Autologous Transplantation Followed by Allogeneic Hematopoietic Cell Transplantation for Patients with Multiple Myeloma: Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial.

Figure 2A: Progression-free survival of standard risk auto-auto and auto-allo groups
Figure 2B: Overall survival of standard risk auto-auto and auto-allo groups.
Figure 2C: Cumulative incidence of disease progression or relapse for standard risk auto-auto and auto-allo groups.
Figure 2D: Cumulative incidence of transplant-related mortality for standard risk auto-auto and auto-allo groups.

Amrita Krishnan, et al. Lancet Oncol. 2011 December;12(13):1195-1203.
3.
Figure 1

Figure 1. From: Tandem Autologous versus Single Autologous Transplantation Followed by Allogeneic Hematopoietic Cell Transplantation for Patients with Multiple Myeloma: Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial.

Study schema outlying the number of patients at each step of the trial.
*Primary analysis of the clinical trial focused on patients meeting protocol criteria of standard risk multiple myeloma. Biologic assignment occurred when HLA-typing results were available after enrollment. Randomization to Thal/Dex or Observation occurred once patients were assigned to auto-auto group. Abbreviations: Mel200, melphalan 200mg/m2; TBI; total body irradiation; Thal/Dex, thalidomide and dexamethasone.

Amrita Krishnan, et al. Lancet Oncol. 2011 December;12(13):1195-1203.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk